Bristol-Myers Squibb appoints Saurabh Saha as SVP
Dr. Saha’s extensive research experience includes leading groundbreaking translational research and implementing innovative drug discovery strategies that have resulted in the discovery and development of two first-in-class cancer therapies and the pioneering of new approaches for unmet medical needs across therapeutic areas and clinical modalities.
Prior to joining Bristol-Myers Squibb, Dr. Saha was a venture partner at Atlas Venture where he held leadership positions with many of its portfolio biotech companies, including as chief medical officer of Synlogic, and as chief executive officer of Delinia until its sale to Celgene in early 2017.
In 2008, Dr. Saha established the translational research and development organization BioMed Valley Discoveries where he served as chief scientific officer and later president.
Earlier in his career, he was a consultant in the pharmaceutical practice at McKinsey and Company and subsequently appointed director and head of the New Indications Discovery Unit at Novartis.
Dr. Saha is on the editorial boards of numerous prestigious medical journals and is an associate member and global clinical scholar at Harvard Medical School.
Dr. Saha holds an M.D. and Ph.D. in cancer genetics from The Johns Hopkins School of Medicine, where he completed his graduate studies in Bert Vogelstein’s lab.
He is an alumnus of Harvard Business School and Oxford University, studying general management and biophysics respectively.
Dr. Saha completed his undergraduate studies in biochemistry from the California Institute of Technology (Caltech).